Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 7;22(2):66.
doi: 10.1208/s12249-021-01939-6.

Emerging Multi-Drug Eutectics: Opportunities and Challenges

Jamshed Haneef  1 , Shakir Ali  2 , Renu Chadha  3
Affiliations
Review

Emerging Multi-Drug Eutectics: Opportunities and Challenges

Jamshed Haneef et al. AAPS PharmSciTech. .

Abstract

Complexity and heterogeneous nature of most diseases have posed greater challenges in the modern healthcare system. Fixed-dose combination can offer an ideal way to improve patient compliance and higher therapeutic efficacy. However, biopharmaceutical issues associated with the drug combinations remain unaddressed. Multidrug eutectics (MDE) have demonstrated significant promise in improving the biopharmaceutical attributes with synergistic therapeutic action. Eutectic mixtures are the multicomponent solid forms that possess lesser melting point than the individual components at a fixed composition. Non-covalent linking of drug combinations as MDE is an innovative strategy with enhanced solubility, dissolution, and mechanical and potential therapeutic efficacy. This review provides a comprehensive overview of the design of MDE, rational selection of drugs, characterization tools, and their therapeutic potential. Besides, the futuristic perspective where MDE could make a significant impact on combination therapy is briefly outlined. Graphical Abstract.

Keywords: crystal engineering; eutectic mixtures; fixed-dose combination; non-covalent derivative; thermal analysis.

PubMed Disclaimer

References

    1. Vermeire E, Hearnshaw H, Van Royen P, Denekens J. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther 2001;26(5):331-342. https://doi.org/10.1046/j.1365-2710.2001.00363.x .
    1. Pourkavoos N. Unique risks, benefits, and challenges of developing drug–drug combination products in a pharmaceutical industrial setting. Comb Prod Ther. 2012;2(1):2. https://doi.org/10.1007/s13556-012-0002-2 . - DOI
    1. Kawalec P, Holko P, Gawin M, Pilc A. Effectiveness of fixed-dose combination therapy in hypertension: systematic review and meta-analysis. Arch Med Sci. 2018;14(5):1125–36. https://doi.org/10.5114/aoms.2018.77561 . - DOI - PubMed - PMC
    1. Kumar V, Prasad B, Singh S. Pharmaceutical issues in the development of a polypill for the treatment of cardiovascular diseases. Drug Discov Today: Ther Strateg. 2008;5(1):63–71. https://doi.org/10.1016/j.ddstr.2008.03.001 . - DOI
    1. Desai D, Wang J, Wen H, Li X, Timmins P. Formulation design, challenges, and development considerations for fixed dose combination (FDC) of oral solid dosage forms. Pharm Dev Technol. 2013;18(6):1265–76. https://doi.org/10.3109/10837450.2012.660699 . - DOI - PubMed

Substances

LinkOut - more resources